Gain Therapeutics, Inc. (GANX) – What Are Analysts Thinking About This Stock?

Shares of Gain Therapeutics, Inc. (NASDAQ:GANX) have been assigned an average recommendation of “Moderate Buy” from the five ratings firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $7.67.

Several equities research analysts have recently issued reports on the stock. BTIG Research reissued a “buy” rating and issued a $5.00 price objective on shares of Gain Therapeutics in a research report on Monday, October 5th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Gain Therapeutics in a report on Friday, September 4th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $8.00 price target on shares of Gain Therapeutics in a research note on Monday, October 5th.

Gain Therapeutics Trading Down 3.5%

Shares of GANX stock opened at $1.11 on Thursday. The firm has a market cap of $48.44 million, a P/E ratio of -2.22 and a beta of 0.29. Gain Therapeutics has a 1-year low of $1.10 and a 1-year high of $4.34. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.36 and a quick ratio of 4.36. The firm’s 50-day simple moving average is $1.57 and its 200-day simple moving average is $1.85.

Gain Therapeutics (NASDAQ:GANX) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.03. As a group, equities analysts forecast that Gain Therapeutics will post -0.50 EPS for the current year.

Institutional Trading of Gain Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. GSA Capital Partners LLP acquired a new stake in Gain Therapeutics during the 2nd quarter valued at approximately $1,283,000. Hohimer Wealth Management LLC purchased a new position in shares of Gain Therapeutics during the 3rd quarter valued at approximately $571,000. BlackRock Inc. purchased a new position in shares of Gain Therapeutics during the 2nd quarter valued at approximately $558,000. Squarepoint Ops LLC acquired a new stake in shares of Gain Therapeutics during the second quarter worth approximately $277,000. Finally, Apollon Wealth Management LLC grew its position in shares of Gain Therapeutics by 33.7% during the first quarter. Apollon Wealth Management LLC now owns 26,500 shares of the company’s stock worth $51,000 after buying an additional 6,675 shares in the last quarter. 11.97% of the stock is owned by hedge funds and other institutional investors.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc is a biotechnology company focused on developing small-molecule therapies for diseases associated with lysosomal dysfunction, including neurodegenerative and rare disorders. The company’s approach is designed to identify compounds that bind to and modulate disease-related proteins, with the goal of restoring their function and addressing underlying disease mechanisms.

Gain Therapeutics’ lead investigational program, GT-02287, is an orally administered, brain-penetrant small molecule being developed for GBA1-associated Parkinson’s disease.